Ceeto Capital Group’s Biogen BIIB Stock Holding History

Ceeto Capital Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,000	Closed	-$480K	–	152
2021 Q4	$480K	Buy	+2,000	New	+$514K	0.2%	102

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Ceeto Capital Group's BIIB Position: Q1 2022 in Review

Ceeto Capital Group sold out of Biogen (BIIB) in Q1 2022, closing a stake of 2,000 shares — an estimated $480K sold.

Ceeto Capital Group first reported a position in BIIB in Q4 2021 and held it in 1 quarter. The position peaked at $480K in Q4 2021. 952 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

Ceeto Capital Group reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
Ceeto Capital Group sold 2,000 Biogen shares in Q1 2022, an estimated $480K.
Ceeto Capital Group first reported a position in Biogen in Q4 2021 and held it in 1 quarter.
Ceeto Capital Group's Biogen position peaked at $480K in Q4 2021.
952 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Ceeto Capital Group's 13F filing for Q1 2022, filed 16 May 2022.